start with what is known
CJC-1295 was made to keep growth-hormone release going longer
Small early studies found hormone rises lasting for days. They cannot settle whether anyone grew healthier or years of use are safe.
CJC-1295 kept growth hormones raised for days
CJC-1295 is called a peptide because a brief string of protein pieces forms it. Here, the small studies come first, along with their limits for you.
Your body sends a natural order to the growth gland at the brain's base. That order contains 29 parts of a protein.
Researchers altered parts 2, 8, 15, and 27 so your body took longer to break the order apart [1]. This let CJC-1295 stay and act longer.
DAC, the added piece, grips albumin [1]. Albumin is one blood protein, and holding it delays removal of CJC-1295.
One small study set each shot by the person's weight. It used 30 or 60 micrograms per kilogram. The word microgram means a very tiny part of one gram.
Growth hormone rose 2- to 10-fold. IGF-1, a blood protein made after growth hormone rises, went up 1.5- to 3-fold for days [2].
The study estimated a 5.8-8.1 day half-life, the time needed to remove half the drug. Those figures describe blood changes, not whether treatment helps you or stays safe over years.
CJC-1295 is not approved care
No health agency has approved CJC-1295 for people [9]. You therefore have no proved treatment amount or years of safety work to rely on.
Two small Phase 1 studies, first tests of how a drug acts, used healthy adults [2][3]. Growth hormone and IGF-1, the growth-linked blood protein, rose longer, but no one showed a health benefit.
A later paper found several other blood proteins changing as that protein rose [5]. The finding confirmed a body response without showing that anyone felt better.
A Phase 2 study, an early test for benefit, used patients with HIV and excess fat around internal organs. It ended, and the public record neither explains why nor ties the stop to harm [9].
The drug fails as a pill, so the studies used shots [9]. Athletic rules forbid it every day, and drug tests can detect it [6][9].
The pages ahead cover study amounts, possible harms, and the drug's two forms. They give you evidence without telling you to use CJC-1295.
The pair raises more hormone, and the two forms last differently
Two mix-ups can lead you to read a claim the wrong way. One concerns the drug pair; the other concerns which CJC-1295 form was used.
CJC-1295 and ipamorelin reach separate places on the growth gland. The hormone rise from both drugs exceeded their separate rises added together [7].
The long CJC-1295 form uses DAC, letting the drug travel beside a blood protein. Modified GRF is the brief form without DAC, so your body removes it sooner [1].
Timing from one form may not fit the other. The pages ahead name the CJC-1295 form whenever that detail matters to you.
Numbered marks show where each fact came from
A bracketed number points you to the paper behind that CJC-1295 fact. The research page covers the CJC-1295/ipamorelin pair, while other pages explain timing.
No fair test has found better health from the pair in healthy adults. No study has established a safe personal amount or settled harm over years [9].
Keep those missing answers in mind while judging any claim. A changed blood test can't prove that your health improved.
Personal accounts are not trial proof
The Benefits, Risks page labels what people say happened while using the drug. No study tested those accounts by comparing a treated group with a similar untreated group.